Literature DB >> 12162910

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.

Edward A Stadtmauer1.   

Abstract

Options for treatment of poor-prognosis or relapsed acute myeloid leukemia (AML) remain limited. Gemtuzumab ozogamicin (Mylotarg, Wyeth-Ayerst, Philadelphia, PA) is an immunoconjugate composed of recombinant humanized murine anti-CD33 antibody linked to calicheamicin, a potent cytotoxic agent. Phase II trials have shown the efficacy of gemtuzumab ozogamicin in the treatment of relapsed AML. Trials exploring this agent in other CD33+ hematologic malignancies and in combination with other agents for AML are ongoing. Gemtuzumab ozogamicin is associated with acceptable toxicity as a single agent. However, the incidence of veno-occlusive disease of the liver remains a concern when this agent is used in combination with chemotherapy or in the context of hematopoietic stem cell transplant.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12162910     DOI： 10.1007/s11912-002-0030-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  4 in total

1.  Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.

Authors:  E L Sievers; F R Appelbaum; R T Spielberger; S J Forman; D Flowers; F O Smith; K Shannon-Dorcy; M S Berger; I D Bernstein
Journal:  Blood       Date:  1999-06-01       Impact factor: 22.113

2.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.

Authors:  E L Sievers; R A Larson; E A Stadtmauer; E Estey; B Löwenberg; H Dombret; C Karanes; M Theobald; J M Bennett; M L Sherman; M S Berger; C B Eten; M R Loken; J J van Dongen; I D Bernstein; F R Appelbaum
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 44.544

3.  Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.

Authors:  F J Giles; H M Kantarjian; S M Kornblau; D A Thomas; G Garcia-Manero; T A Waddelow; C L David; A T Phan; D E Colburn; A Rashid; E H Estey
Journal:  Cancer       Date:  2001-07-15       Impact factor: 6.860

Review 4.  Treatment of relapsed and refractory acute myelogenous leukemia.

Authors:  E H Estey
Journal:  Leukemia       Date:  2000-03       Impact factor: 11.528
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.